扶正消积汤联合吉西他滨及顺铂治疗非小细胞肺癌临床研究

Clinical Study on Fuzheng Xiaoji Decoction Combined with Gemcitabine and Cisplatin in the Treatment of Non-small Cell Lung Cancer

目的探讨非小细胞肺癌临床治疗中扶正消积汤联合吉西他滨及顺铂治疗的价值。方法以随机数字表法,将2016年2月—2017年2月就诊于我院的90例非小细胞肺癌患者分为吉西他滨及顺铂治疗的对照组与扶正消积汤联合吉西他滨及顺铂治疗的观察组,每组45例患者。对比分析两组患者的临床治疗效果。结果在临床治疗总有效率方面,观察组与对照组分别为75.56%与57.78%,两组组间相比,差异具有统计学意义(P<0.05);在不良反应发生率方面,观察组与对照组分别为35.56%与64.44%,组间相比,差异具有统计学意义(P<0.05)。结论在非小细胞肺癌患者的临床治疗中,采用中西医结合治疗方案具有较为显著的优势,且不良反应较少,值得临床广泛应用。

Objective To explore the value of Fuzheng Xiaji decoction combined with gemcitabine and cisplatin in the clinical treatment of non-small cell lung cancer. Methods According to the random number table method,90 patients with non-small cell lung cancer who were treated in our hospital from February 2016 to February 2017 were divided into gemcitabine and cisplatin-treated control group and Fuzheng Xiaojie combined with gemcitabine and cisplatin treatment group,and each group had 45 patients. The clinical curative effect was compared.Results The total effective rate of the observation group and the control group were 75. 56% and 57. 78% respectively,and the difference was statistically significant（ P〈0. 05）. The incidence of adverse reactions of the observation group and the control group were 35. 56% and 64. 44% respectively,and the difference was statistically significant（ P〈0. 05）. Conclusion In the clinical treatment of patients with non-small cell lung cancer,the combination of traditional Chinese and Western medicine has a significant advantage,and patients with less adverse reactions,and is worthy of clinical widely application.